Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Palani LLC is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity is limited to 1 distinct examiner and 1 distinct art unit, reflecting a specific technical and procedural focus. The Biotechnology & Pharmaceuticals area often involves complex biological data, and the concentration in 1 distinct art unit suggests a specialized application of these technologies.
The busiest examiner for this portfolio is NEAGU, IRINA, who is responsible for 1 pending. As the only examiner currently engaged with the company's pending workload, the prosecution timeline is dependent on the specific review pace of this individual. This creates a direct line of communication between the applicant and the examiner, simplifying the negotiation process for the pending matter.
With 1 pending office action, the portfolio does not face the challenges of managing multiple simultaneous responses. The use of 1 distinct art unit means that the applicant can focus on the specific examination standards and prior art landscape relevant to that unit. Practitioners should carefully review the specific objections raised by NEAGU, IRINA to ensure a comprehensive response that addresses all concerns in the Biotechnology & Pharmaceuticals space.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEAGU, IRINA | 1 | 46.8% | +57.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998161 | A FATTY ACID BASED COMPOSITION FOR TREATMENT AND/OR PREVENTION OF ENVELOPED-VIRUS RELATED INFECTIONS | NEAGU, IRINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998161 | A FATTY ACID BASED COMPOSITION FOR TREATMENT AND/OR PREVENTION OF ENVELOPED-VIRUS RELATED INFECTIONS | NEAGU, IRINA | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17998161 | A FATTY ACID BASED COMPOSITION FOR TREATMENT AND/OR PREVENTION OF ENVELOPED-VIRUS RELATED INFECTIONS | NEAGU, IRINA | 1629 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPalani LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Irina Neagu has the most, with 1 of Palani LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.